BioCentury | Apr 1, 2020
Emerging Company Profile

Affinia: Optimizing for AAV vector function

With a $60 million series A round, a pair of gene therapy veterans at the helm and a platform designed by the co-inventor of the AAV9 vector, Affinia Therapeutics is developing gene therapies based on...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline. In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...
BC Extra | Nov 1, 2019
Politics & Policy

Trump administration shifts Sharpless to make way for Hahn

The Trump administration has launched a game of musical chairs that is intended to clear a path for Stephen Hahn to be confirmed as FDA commissioner. When the music stops, it is possible that Hahn...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BC Extra | Aug 29, 2019
Politics & Policy

Clock ticking on Sharpless' term as acting FDA commissioner

Time may be running out on Ned Sharpless’ term as acting FDA commissioner. President Donald Trump must make a decision about the agency's top job by Nov. 1. If the White House decides to seek...
BC Innovations | Aug 14, 2019
Distillery Therapeutics

RASGRF2-MEK inhibition for cocaine addiction

DISEASE CATEGORY: Neurology INDICATION: Addiction Blocking phosphorylation of MAPK1 and MAPK3 in the nucleus accumbens region of the brain by inhibiting RASGRF2-MEK signaling could treat cocaine addiction. In a mouse model of the addiction, the...
BioCentury | Aug 14, 2019

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

With nothing left to prove in an academic setting, five-year-old Renovacor has attracted an $11 million series A round designed to complete preclinical testing of its gene therapy for a rare form of dilated cardiomyopathy....
Items per page:
1 - 10 of 154